{"id":80101,"date":"2026-05-11T23:34:19","date_gmt":"2026-05-11T23:34:19","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/80101\/"},"modified":"2026-05-11T23:34:19","modified_gmt":"2026-05-11T23:34:19","slug":"novo-transfers-parkinsons-therapy-to-zuckerberg-backed-cellular-intelligence","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/80101\/","title":{"rendered":"Novo Transfers Parkinson\u2019s Therapy to Zuckerberg-Backed Cellular Intelligence"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">Novo Nordisk A\/S agreed to hand over an experimental therapy for Parkinson\u2019s disease to a Mark Zuckerberg-backed AI startup to potentially speed its development. <\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">The startup, <a href=\"https:\/\/www.cellularintelligence.com\/science\" title=\"Firm&#039;s Website\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Cellular Intelligence<\/a>, is gaining rights to the early-stage treatment and will be in charge of shepherding it through clinical trials, it said Monday. Novo, the maker of the obesity blockbuster Wegovy, stands to receive milestone payments and royalties if the program succeeds. The Danish drugmaker agreed to buy a stake in the Boston-based startup as part of the deal. No financial details were disclosed.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S agreed to hand over an experimental therapy for Parkinson\u2019s disease to a Mark Zuckerberg-backed AI&hellip;\n","protected":false},"author":2,"featured_media":80102,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[1204,9840,726,8698,1585,730,42693,272,13578,21306,685,591,239],"class_list":{"0":"post-80101","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-artificial-intelligence","9":"tag-cancer","10":"tag-chief-executive-officer","11":"tag-engineering","12":"tag-government","13":"tag-industries","14":"tag-mark-elliot-zuckerberg","15":"tag-novo-nordisk","16":"tag-novo-nordisk-a-s-b","17":"tag-pharmaceutical","18":"tag-regulation","19":"tag-startups","20":"tag-technology"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116558565638106544","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/80101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=80101"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/80101\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/80102"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=80101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=80101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=80101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}